UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): May 20, 2019
 
REZOLUTE, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
 
000-54495
 
27-3440894
(State or Other Jurisdiction
of Incorporation)
 
(Commission File Number)
 
(I.R.S. Employer
Identification No.)
 
 
 
201 Redwood Shores Pkwy, Suite 315,
Redwood City, CA
 

94065
(Address of Principal Executive Offices)
 
(Zip Code)
 
 
 
 
 
 
 
 
Registrant’s Telephone Number, Including Area Code: (650) 206-4507
 
(Former Address, Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 Securities registered or to be registered pursuant to Section 12(b) of the Act.

     

Title of each class
Trading
Symbol(s)

Name of each exchange on which registered
N/A
N/A
N/A


 
Item 7.01 Regulation FD Disclosure.

On May 15th, 2019, Rezolute, Inc. (the “Company”) resumed its Phase 1 first-in-human clinical trial of AB101 (AB101-01), with dosing of the first patient in the second cohort. It is anticipated that this second cohort will enroll up to 8 patients and will conclude in the 3rd quarter of 2019. Top-line results are expected prior to year end. Depending upon results, the Company may explore partnering opportunities for the program.

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



  
REZOLUTE, INC.
 
 
Date: May 20, 2019
By: 
/s/ Keith Vendola
 
 
Name: Keith Vendola
Title: Chief Financial Officer